A 12-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Antihypertensive Efficacy and Safety of an Exforge (Valsartan/Amlodipine)-Based Regimen Versus a Losartan-Based Regimen in Patients With Stage 2 Systolic Hypertension.

Trial Profile

A 12-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Antihypertensive Efficacy and Safety of an Exforge (Valsartan/Amlodipine)-Based Regimen Versus a Losartan-Based Regimen in Patients With Stage 2 Systolic Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2011

At a glance

  • Drugs Amlodipine/valsartan; Amlodipine/valsartan/hydrochlorothiazide; Losartan; Losartan/hydrochlorothiazide
  • Indications Hypertension
  • Focus Therapeutic Use
  • Acronyms EXALT
  • Sponsors Novartis
  • Most Recent Events

    • 10 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top